Jiangsu Nanfang Medical (603880) — Capital Reinvestment Ratio

Latest as of September 2025: 0.18x

Jiangsu Nanfang Medical (603880) has a Capital Reinvestment Ratio of 0.18x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥12.53 Million) in capital expenditures (CN¥2.25 Million). See 603880 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

0.18x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥12.53 Million
CNY

Capital Expenditures

CN¥2.25 Million
CNY

Data as of

Sep 2025
Most recent filing

Jiangsu Nanfang Medical Capital Reinvestment Ratio (2012–2025)

This chart tracks Jiangsu Nanfang Medical's Capital Reinvestment Ratio across 13 annual periods.

Annual Capital Reinvestment Ratio for Jiangsu Nanfang Medical (2012–2025)

Year-by-year Capital Reinvestment Ratio for Jiangsu Nanfang Medical from 2012 to 2025. For live market cap and broader valuation context, see Jiangsu Nanfang Medical market capitalisation.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2025 0.28x CN¥47.73 Million CN¥13.20 Million ▼ -46.0%
2024 0.51x CN¥63.32 Million CN¥32.41 Million ▼ -88.0%
2023 4.27x CN¥15.51 Million CN¥66.16 Million ▼ -8.7%
2022 4.67x CN¥31.28 Million CN¥146.16 Million ▲ +484.2%
2020 0.80x CN¥154.12 Million CN¥123.29 Million ▼ -53.2%
2019 1.71x CN¥32.99 Million CN¥56.36 Million ▲ +15.9%
2018 1.47x CN¥52.75 Million CN¥77.76 Million ▲ +133.1%
2017 0.63x CN¥49.24 Million CN¥31.14 Million ▲ +16.3%
2016 0.54x CN¥99.35 Million CN¥54.03 Million ▲ +11.3%
2015 0.49x CN¥90.66 Million CN¥44.30 Million ▲ +417.8%
2014 0.09x CN¥73.52 Million CN¥6.94 Million ▼ -93.4%
2013 1.43x CN¥20.14 Million CN¥28.81 Million ▲ +409.4%
2012 0.28x CN¥76.07 Million CN¥21.36 Million —
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow